NZ572012A - Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines - Google Patents

Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines

Info

Publication number
NZ572012A
NZ572012A NZ572012A NZ57201207A NZ572012A NZ 572012 A NZ572012 A NZ 572012A NZ 572012 A NZ572012 A NZ 572012A NZ 57201207 A NZ57201207 A NZ 57201207A NZ 572012 A NZ572012 A NZ 572012A
Authority
NZ
New Zealand
Prior art keywords
composition
taxane
iponz
alkyl
received
Prior art date
Application number
NZ572012A
Other languages
English (en)
Inventor
Richard D Olson
Gerald M Walsh
Original Assignee
Gem Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gem Pharmaceuticals Llc filed Critical Gem Pharmaceuticals Llc
Publication of NZ572012A publication Critical patent/NZ572012A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ572012A 2006-04-21 2007-04-23 Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines NZ572012A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/408,000 US7776832B2 (en) 2006-04-21 2006-04-21 Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
PCT/US2007/067225 WO2007124489A2 (en) 2006-04-21 2007-04-23 Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines

Publications (1)

Publication Number Publication Date
NZ572012A true NZ572012A (en) 2011-09-30

Family

ID=38620193

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ572012A NZ572012A (en) 2006-04-21 2007-04-23 Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines

Country Status (20)

Country Link
US (2) US7776832B2 (pl)
EP (1) EP2010191B1 (pl)
JP (1) JP5011377B2 (pl)
KR (1) KR101514336B1 (pl)
CN (1) CN101426509A (pl)
AU (1) AU2007240264B2 (pl)
CA (1) CA2649753C (pl)
CO (1) CO6190526A2 (pl)
DK (1) DK2010191T3 (pl)
ES (1) ES2840977T3 (pl)
IL (1) IL194707A (pl)
MX (1) MX2008013546A (pl)
MY (1) MY148571A (pl)
NZ (1) NZ572012A (pl)
PL (1) PL2010191T3 (pl)
PT (1) PT2010191T (pl)
RU (1) RU2421224C2 (pl)
UA (1) UA90597C2 (pl)
WO (1) WO2007124489A2 (pl)
ZA (1) ZA200808892B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110111321A (ko) * 2009-01-30 2011-10-10 이난타 파마슈티칼스, 인코포레이티드 C형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) * 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) * 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
EP3154586B1 (en) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Treating lymphomas
MX2016016617A (es) 2014-06-16 2017-03-23 Mayo Foundation Tratamiento de mielomas.
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
EP3265059A4 (en) * 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
CA3018340A1 (en) * 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
KR20220151022A (ko) 2016-09-01 2022-11-11 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체-pd-l1 결합제 조성물
MX2019002473A (es) 2016-09-01 2019-09-18 Mayo Found Medical Education & Res Métodos y composiciones para el direccionamiento de cánceres de células t.
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CA3035653A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
CA3035655A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
US10450340B2 (en) * 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
RU2764724C2 (ru) * 2017-03-16 2022-01-19 ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД. Комбинированная терапия для лечения рака молочной железы

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1098211B (it) * 1978-05-09 1985-09-07 Farmaceutici Italia Deossiantracicline antitumorali
US5948896A (en) 1997-08-13 1999-09-07 Gem Pharmaceuticals Processes for preparing 13-deoxy anthracycline derivatives
US5942605A (en) 1998-03-03 1999-08-24 Gem Pharmaceuticals, Inc. 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them
PL350042A1 (en) 1999-01-13 2002-10-21 Genentech Inc Serine protease inhibitors
GB9909925D0 (en) 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
MXPA04010640A (es) * 2002-05-17 2005-08-16 Aventis Pharma Sa Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario.
US9904704B2 (en) 2014-04-22 2018-02-27 Openx Software Limited System and method for controlling audience data and tracking

Also Published As

Publication number Publication date
US7776832B2 (en) 2010-08-17
CA2649753C (en) 2011-09-27
ES2840977T3 (es) 2021-07-07
PT2010191T (pt) 2021-01-04
IL194707A (en) 2015-10-29
CO6190526A2 (es) 2010-08-19
KR20090010981A (ko) 2009-01-30
EP2010191A4 (en) 2010-05-26
PL2010191T3 (pl) 2021-05-04
IL194707A0 (en) 2009-08-03
WO2007124489A3 (en) 2008-10-23
AU2007240264A1 (en) 2007-11-01
DK2010191T3 (da) 2020-12-14
EP2010191A2 (en) 2009-01-07
ZA200808892B (en) 2009-10-28
CA2649753A1 (en) 2007-11-01
EP2010191B1 (en) 2020-10-07
MX2008013546A (es) 2009-01-20
RU2421224C2 (ru) 2011-06-20
KR101514336B1 (ko) 2015-04-22
BRPI0711256A2 (pt) 2011-08-30
US20100311679A1 (en) 2010-12-09
UA90597C2 (ru) 2010-05-11
MY148571A (en) 2013-04-30
US20070249547A1 (en) 2007-10-25
WO2007124489A2 (en) 2007-11-01
JP2009534426A (ja) 2009-09-24
CN101426509A (zh) 2009-05-06
US8158591B2 (en) 2012-04-17
RU2008141682A (ru) 2010-05-27
AU2007240264B2 (en) 2012-11-01
JP5011377B2 (ja) 2012-08-29

Similar Documents

Publication Publication Date Title
NZ572012A (en) Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
AU773506B2 (en) Antitumour synergistic composition
UA97351C2 (ru) Производная кумарина, имеющая противоопухолевую активность
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
WO2009120697A4 (en) Method and compositions for treatment of cancer
IL197513A0 (en) Pyrazolopyrimidine derivatives and pharmaceutical compositions containing the same
MX2010002932A (es) Macrolidos de biarilo con puente en 6, 11.
IL229594A (en) Derived Lactone Derivatives, Pharmaceutical Compositions Containing Them and Their Uses in the Preparation of Medical Preparations for Cancer Treatment
RU2009107085A (ru) Способы, композиции и изделия, способствующие лечению рака
TW200634021A (en) 3,6-bicyclolides
AU2001278463B2 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
AU2001278463A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
WO2009053654A3 (fr) Prodrogues phosphoesters de la gemcitabine comme agents anticancereux
NZ595615A (en) Combination therapy against cancer utilising 3-beta-cholestanyl-3-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-beta-D-galactopyranoside and is derivatives
WO2007044927A3 (en) 6, 11-bridged tricyclic macrolides
WO2006065743A3 (en) Tetracylic bicyclolides
WO2008014221A3 (en) Bridged carbamate macrolides
MX2012005618A (es) Derivados de lactona macrociclica para el tratamiento del cancer.
WO2008019240A3 (en) 3, 6-bridged tylosin derivatives
US20070249651A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors
WO2008117775A1 (ja) オキセタン環構造を有するタキサン化合物
WO2006099175A3 (en) Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
PE20080282A1 (es) Combinaciones antitumorales que contienen derivados de taxano
MY144013A (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 APR 2017 BY CPA GLOBAL

Effective date: 20140417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2018 BY CPA GLOBAL

Effective date: 20170311

LAPS Patent lapsed